Welcome!

SYS-CON UK Authors: Salvatore Genovese, Jamie Matusow

News Feed Item

Coyote Pharmaceuticals to Present at Biotech Showcase™ 2013

MENLO PARK, Calif., Jan. 2, 2013 /PRNewswire/ -- Coyote Pharmaceuticals, Inc., an emerging biopharmaceutical company focused on neurodegenerative diseases, announced today that President and CEO, Hiroaki Serizawa, Ph.D. will present at the Biotech Showcase™ 2013 Conference being held in San Francisco January 7-9, 2013.  Dr. Serizawa will provide an overview of the company's lead compound, CNS-102, which will soon enter clinical development for amyotrophic lateral sclerosis (ALS) and Alzheimer's disease (AD).

Details of Coyote's presentation are as follows:

Event:


Biotech Showcase 2013 Conference

Date: 


Wednesday, January 9, 2013

Time: 


2:45 pm PST

Location:


Parc 55 Wyndham San Francisco Union Square Hotel

Biotech Showcase is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present and meet with investors and pharmaceutical executives during the course of one of the industry's largest annual healthcare investor conferences.  Investors and biopharmaceutical executives from around the world gather in San Francisco during this critical week, which is widely viewed as setting the tone for the coming year.

About Coyote Pharmaceuticals:

Coyote Pharmaceuticals, Inc. is an emerging biopharmaceutical company focused on treating neurodegenerative diseases through the modulation of protein folding and transport vital to maintaining cellular homeostasis.  The company's lead drug candidate, CNS-102, is being developed initially to treat amyotrophic lateral sclerosis (ALS) and Alzheimer's disease (AD).  The orally bioavailable small molecule therapeutic is designed to activate gene expression of a family of proteins – known as heat shock proteins – involved in regulating the folding and transport of other proteins. Heat shock proteins are capable of preventing and repairing the pathophysiological aggregation of other cellular proteins, which are implicated in the etiology of ALS and AD.  For more information on Coyote visit http://www.coyotepharma.com.

For Media & Investors:
Jason Rando / Joshua Drumm, Ph.D.
Tiberend Strategic Advisors, Inc.
(212) 827-0020
jrando@tiberend.com
jdrumm@tiberend.com

 

SOURCE Coyote Pharmaceuticals, Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.